Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neuropsychology Review
Published in: Neuropsychology Review 4/2009

01-12-2009 | Review

Beta-Amyloid Deposition and the Aging Brain

Authors: Karen M. Rodrigue, Kristen M. Kennedy, Denise C. Park

Published in: Neuropsychology Review | Issue 4/2009

Login to get access

Abstract

A central issue in cognitive neuroscience of aging research is pinpointing precise neural mechanisms that determine cognitive outcome in late adulthood as well as identifying early markers of less successful cognitive aging. One promising biomarker is beta amyloid (Aβ) deposition. Several new radiotracers have been developed that bind to fibrillar Aβ providing sensitive estimates of amyloid deposition in various brain regions. Aβ imaging has been primarily used to study patients with Alzheimer’s Disease (AD) and individuals with Mild Cognitive Impairment (MCI); however, there is now building data on Aβ deposition in healthy controls that suggest at least 20% and perhaps as much as a third of healthy older adults show significant deposition. Considerable evidence suggests amyloid deposition precedes declines in cognition and may be the initiator in a cascade of events that indirectly leads to age-related cognitive decline. We review studies of Aβ deposition imaging in AD, MCI, and normal adults, its cognitive consequences, and the role of genetic risk and cognitive reserve.
Footnotes
1
This bimodal distribution may serve to highlight the arbitrary nature of a categorical MCI group and emphasizes the continuum of cognitive performance from normal to AD, with MCI being a mid-point of this continuum.
 
Literature
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., et al. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65, 1509–1517.CrossRefPubMed
Andreasen, N., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B., et al. (1999). Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neuroscience Letters, 273, 5–8.CrossRefPubMed
Andrews-Hanna, J. R., Snyder, A. Z., Vincent, J. L., Lustig, C., Head, D., Raichle, M. E., et al. (2007). Disruption of large-scale brain systems in advanced aging. Neuron, 56, 924–935.CrossRefPubMed
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 66, 1837–1844.CrossRefPubMed
Bourgeat, P., Villemagne, V.L., Fripp, J., Pike, K.E., Raniga, P., Acosta, O., et al. (2009). Relation between amyloid burden, brain atrophy and memory in Alzheimer’s disease. Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD 2009), July.
Braak, H., & Braak, E. (1996). Evolution of the neuropathology of Alzheimer’s disease. Acta Neurologica Scandinavica, 165, 3–12.
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., et al. (2005). Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience, 25, 7709–7717.CrossRefPubMed
Buckner, R. L., Andrews-Hanna, J. R., & Schacter, D. L. (2008). The brain’s default network: anatomy, function, and relevance to disease. Annals of the New York Academy of Sciences, 1124, 1–38.CrossRefPubMed
Buckner, R. L., Sepulcre, J., Talukdar, T., Krienen, F. M., Liu, H., Hedden, T., et al. (2009). Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. Journal of Neuroscience, 29, 1860–1873.CrossRefPubMed
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261, 921–923.CrossRefPubMed
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., et al. (2009). The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex, 19, 497–510.CrossRefPubMed
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., et al. (1992). Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiology of Aging, 13, 179–189.CrossRefPubMed
Diniz, B. S., Pinto, J. A., & Forlenza, O. V. (2008). Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World Journal of Biological Psychiatry, 9, 172–182.CrossRefPubMed
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., et al. (2009). Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology, 72, 1487–1494.CrossRefPubMed
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., et al. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology, 68, 501–508.CrossRefPubMed
Farlow, M. R., He, Y., Tekin, S., Xu, J., Lane, R., & Charles, H. C. (2004). Impact of APOE in mild cognitive impairment. Neurology, 63, 1898–1901.PubMed
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease meta analysis consortium. Journal of the American Medical Association, 278, 1349–1356.CrossRefPubMed
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., et al. (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 29, 1456–1465.CrossRefPubMed
Fotenos, A. F., Mintun, M. A., Snyder, A. Z., Morris, J. C., & Buckner, R. L. (2008). Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Archives of Neurology, 65, 113–120.CrossRefPubMed
Fripp, J., Bourgeat, P., Acosta, O., Raniga, P., Modat, M., Pike, K. E., et al. (2008). Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging. Neuroimage, 43, 430–439.CrossRefPubMed
Ghisletta, P., & Lindenberger, U. (2003). Age-based structural dynamics between perceptual speed and knowledge in the Berlin aging study: direct evidence for ability dedifferentiation in old age. Psychology and Aging, 18, 696–713.CrossRefPubMed
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003). Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proceedings of the National Academy of Sciences of the United States of America, 100, 253–258.CrossRefPubMed
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., et al. (2009). Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biological Psychiatry, 65, 927–934.CrossRefPubMed
Grundman, M., Sencakova, D., Jack, C. R., Jr., Petersen, R. C., Kim, H. T., Schultz, A., et al. (2002). Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience, 19, 23–27.CrossRefPubMed
Gutchess, A. H., Welsh, R. C., Hedden, T., Bangert, A., Minear, M., Liu, L. L., et al. (2005). Aging and the neural correlates of successful picture encoding: frontal activations compensate for decreased medial-temporal activity. Journal of Cognitive Neuroscience, 17, 84–96.CrossRefPubMed
Hedden, T., & Gabrieli, J. D. E. (2004). Insights into the ageing mind: a view from cognitive neuroscience. Nature Reviews Neuroscience, 5, 87–97.CrossRefPubMed
Ichise, M., Plett, S., Joshi, A., Stern, Y., van Heertum, R., Lowe, V., et al. (2008). Quantitative comparison of three novel 18F-labeled ligands for PET imaging of brain amyloid-β plaques in Alzheimer’s disease. Journal of Nuclear Medicine, 49, 214.
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., et al. (2004). Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology, 62, 925–931.PubMed
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., et al. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain, 131, 665–680.CrossRefPubMed
Jack, C. R., Jr., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., et al. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain, 132, 1355–1365.CrossRefPubMed
Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., et al. (2008). ApoE promotes the proteolytic degradation of Abeta. Neuron, 58, 681–693.CrossRefPubMed
Josephs, K. A., Whitwell, J. L., Ahmed, Z., Shiung, M. M., Weigand, S. D., Knopman, D. S., et al. (2008). Beta-amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 63, 204–212.CrossRefPubMed
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., et al. (2003). APP processing and synaptic function. Neuron, 37, 925–937.CrossRefPubMed
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., et al. (1988). Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Annals of Neurology, 23, 138–144.CrossRefPubMed
Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., et al. (2006). Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology, 67, 1575–1580.CrossRefPubMed
Kemppainen, N. M., Aalto, S., Wilson, I. A., Någren, K., Helin, S., Brück, A., et al. (2007). PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology, 68, 1603–1606.CrossRefPubMed
Kemppainen, N. M., Aalto, S., Karrasch, M., Någren, K., Savisto, N., Oikonen, V., et al. (2008). Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer’s disease. Annals of Neurology, 63, 112–118.CrossRefPubMed
Klunk, W. E., & Mathis, C. A. (2008). The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Current Opinion in Neurology, 21, 683–687.CrossRefPubMed
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306–319.CrossRefPubMed
Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., et al. (2008). Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 35, 2169–2181.CrossRefPubMed
Linazasoro, G. (2008). Imaging beta-amyloid burden in aging and dementia. Neurology, 70, 1649–1650.CrossRefPubMed
Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., et al. (2005). Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. Journal of Nuclear Medicine, 46, 1959–1972.PubMed
Mintun, M. A., Larossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., et al. (2006). [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology, 67, 446–452.CrossRefPubMed
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., et al. (2009). Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects. Brain, 132, 1310–1323.CrossRefPubMed
Morris, J. C., Roe, C. M., & Mintun, M. A. (2009). APOE status predicts PiB-positivity in nondemented aging: evidence for Preclinical Alzheimer’s disease. Neurology, 72, A92.CrossRef
Nelissen, N., Vandenbulcke, M., Fannes, K., Verbruggen, A., Peeters, R., Dupont, P., et al. (2007). Abeta amyloid deposition in the language system and how the brain responds. Brain, 130, 2055–2069.CrossRefPubMed
Nitsch, R. M., Farber, S. A., Growdon, J. H., & Wurtman, R. J. (1993). Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proceedings of the National Academy of Sciences, 90, 5191–5193.CrossRef
Nordlund, A., Rolstad, S., Klang, O., Lind, K., Pedersen, M., Blennow, K., et al. (2008). Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. Journal of the International Neuropsychological Society, 14, 582–590.CrossRefPubMed
Park, D. C., & Goh, J. O. (2009). Successful aging. In J. Cacioppo & G. Berntson (Eds.), Handbook of Cognitive Neuroscience for the Behavioral Sciences, Ch. 61 (pp. 1203–1219). Hoboken: Wiley.
Park, D. C., & Reuter-Lorenz, P. A. (2009). The adaptive brain: aging and neurocognitive scaffolding. Annual Review of Psychology, 60, 173–196.CrossRefPubMed
Park, D. C., Lautenschlager, G., Hedden, T., Davidson, N. S., Smith, A. D., & Smith, P. K. (2002). Models of visuospatial and verbal memory across the adult life span. Psychology and Aging, 17, 299–320.CrossRefPubMed
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56, 303–308.CrossRefPubMed
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., et al. (2007). Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain, 130, 2837–2844.CrossRefPubMed
Raz, N., & Rodrigue, K. M. (2006). Differential aging of the brain: patterns, cognitive correlates and modifiers. Neuroscience & Biobehavioral Reviews, 30, 730–748.CrossRef
Raz, N., & Kennedy, K. M. (2009). A systems approach to age-related change: Neuroanatomical changes, their modifiers, and cognitive correlates. In W. Jagust & M. D’Esposito (Eds.), Imaging the aging brain, Ch 4 (pp. 43–70). Oxford UP: NYC.
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences, 106, 6820–6825.CrossRef
Rodrigue, K. M., & Raz, N. (2004). Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. Journal of Neuroscience, 24, 956–963.CrossRefPubMed
Rolstad, S., Nordlund, A., Eckerström, C., Gustavsson, M. H., Zetterberg, H., & Wallin, A. (2009). Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment—proof of concept. Dementia and Geriatric Cognitive Disorders, 27, 194–200.CrossRefPubMed
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., et al. (2007). Imaging beta-amyloid burden in aging and dementia. Neurology, 68, 1718–1725.CrossRefPubMed
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O’Keefe, G., et al. (2008). Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurology, 7, 129–135.CrossRefPubMed
Samuels, S. C., Silverman, J. M., Marin, D. B., Peskind, E. R., Younki, S. G., Greenberg, D. A., et al. (1999). CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease. Neurology, 52, 547–551.PubMed
Scheinin, N.M., Aalto, S., Koikkalainen, J., Lötjönen, J., Karrasch, M., Kemppainen, N., et al. (2009). Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology, 73, 1186–1192.
Schmidt, M. L., Lee, V. M., & Trojanowski, J. Q. (1990). Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. American Journal of Pathology, 136, 1069–1075.
Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., et al. (2002). Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 10, 24–35.PubMed
Skovronsky, D. (2008). Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents. Journal of Nuclear Medicine, 49, 47N–48N.PubMed
Skovronsky, D., Coleman, R. E., Frey, K., Garg, P., Ichise, M., Lowe, V., et al. (2008). Results of multi-center clinical trials comparing four 18F PET amyloid-imaging agents: preclinical to clinical correlations. Journal of Nuclear Medicine Meeting Abstracts, 49(1), 34P.
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., et al. (2006). PET of brain amyloid and tau in mild cognitive impairment. New England Journal of Medicine, 355, 2652–2663.CrossRefPubMed
Small, G. W., Bookheimer, S. Y., Thompson, P. M., Cole, G. M., Huang, S., Kepe, V., et al. (2008). Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurology, 7, 161–172.CrossRefPubMed
Small, G. W., Siddarth, P., Burggren, A. C., Kepe, V., Ercoli, L. M., Miller, K. J., et al. (2009). Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Archives of General Psychiatry, 66, 81–87.CrossRefPubMed
Sperling, R. A., Laviolette, P. S., O’Keefe, K., O’Brien, J., Rentz, D. M., Pihlajamaki, M., et al. (2009). Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron, 63, 178–188.CrossRefPubMed
Stern, Y. (2002). What is cognitive reserve? Theory and research application of the reserve concept. Journal of the International Neuropsychological Society, 8, 448–460.CrossRefPubMed
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003). CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 60, 652–656.PubMed
Tapiola, T., Pirttilä, T., Mikkonen, M., Mehta, P. D., Alafuzoff, I., Koivisto, K., et al. (2000). Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neuroscience Letters, 280, 119–122.CrossRefPubMed
Thal, D.R., Capetillo-Zarate, E., Del Tredici, K., & Braak, H. (2006). The development of amyloid beta protein deposits in the aged brain. Science of Aging Knowledge Environment: SAGE KE, 2006(6), re1.
Tolboom, N., Yaqub, M., van der Flier, W. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., et al. (2009a). Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. Journal of Nuclear Medicine, 50, 191–197.CrossRefPubMed
Tolboom, N., Yaqub, M., Boellaard, R., Luurtsema, G., Windhorst, A.D., Scheltens, P., et al. (2009b). Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging, 36, 1629–1638.
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., et al. (2008). Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer’s disease. Neuropsychologia, 46, 1688–1697.CrossRefPubMed
Wahlund, L. O., & Blennow, K. (2003). Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neuroscience Letters, 339, 99–102.CrossRefPubMed
Wishart, H. A., Saykin, A. J., McAllister, T. W., Rabin, L. A., McDonald, B. C., Flashman, L. A., et al. (2006). Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology, 67, 1221–1224.CrossRefPubMed
Wong, D., Rosenberg, P., Zhou, Y., Kumar, A., Ravert, H., Brasic, J., et al. (2008). In vivo imaging of amyloid deposition in Alzheimer’s disease using the novel radioligand [18F] AV-45. Journal of Nuclear Medicine Meeting Abstracts, 49(1), 214P.
Zhang, W., Kung, M., Oya, S., Hou, C., & Kung, H. F. (2007). 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. Nuclear Medicine and Biology, 34, 89–97.CrossRefPubMed
Metadata
Title
Beta-Amyloid Deposition and the Aging Brain
Authors
Karen M. Rodrigue
Kristen M. Kennedy
Denise C. Park
Publication date
01-12-2009
Publisher
Springer US
Published in
Neuropsychology Review / Issue 4/2009
Print ISSN: 1040-7308
Electronic ISSN: 1573-6660
DOI
https://doi.org/10.1007/s11065-009-9118-x

Other articles of this Issue 4/2009

Neuropsychology Review 4/2009 Go to the issue

Review

Implicit Learning in Aging: Extant Patterns and New Directions

Review

Aging and Spatial Navigation: What Do We Know and Where Do We Go?

Preface

Decline and Compensation in Aging Brain and Cognition: Promises and Constraints

Review

Cerebral White Matter Integrity and Cognitive Aging: Contributions from Diffusion Tensor Imaging

Review

The Impact of Genetic Research on our Understanding of Normal Cognitive Ageing: 1995 to 2009

EDITORIAL POSTSCRIPT

Cognitive Aging Research: An Exciting Time for a Maturing Field